QURE AMT-130 BLA: First Huntington's Gene Therapy Filing

uniQure (QURE) filed a Biologics License Application with the FDA on September 2 seeking accelerated approval of AMT-130, its one-time gene therapy for Huntington’s disease. It also submitted a marketing application to the UK’s MHRA the same day. Shares closed at $46.23, down 4.7% on the news, leaving a roughly $3.3 billion market cap.

AMT-130, formally ifezuntirgene inilparvovec, is an AAV5 vector that delivers a microRNA to silence the huntingtin gene at the source. It is the first Huntington’s drug to hold FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Fast Track designations. uniQure requested priority review, which would compress the review to roughly six months after a 60-day filing-acceptance period.

The application rests on three-year Phase I/II data compared against a propensity-score-matched external control from the Enroll-HD natural history registry, not a randomized trial. At 36 months, high-dose patients showed a 75% slowing of disease progression on the cUHDRS scale (p=0.003). The FDA pushed back hard in November 2025, then reversed course after a June 2026 Type B meeting and agreed the data could support an accelerated approval filing. A prior deep dive on the AMT-130 Huntington’s gene therapy filing covers the science and valuation in full, and the accelerated approval pathway explains what a confirmatory study means here.

Huntington’s is an invariably fatal inherited disorder with no approved disease-modifying therapy. Roche’s RG6042, PTC Therapeutics’ PTC518, and Alnylam’s ALN-HTT02 are all earlier in development, so uniQure holds a multi-year lead.

About 75,000 people have manifest Huntington’s in the US, EU, and UK, with hundreds of thousands more at genetic risk, and the disease progresses relentlessly from motor and cognitive decline to death. AMT-130 is not a pill or an injection: it is delivered by MRI-guided, convection-enhanced neurosurgery directly into the striatum. That surgical complexity, plus AAV5 manufacturing at commercial scale, means a launch would roll out slowly through a limited number of specialized centers.

The catch is the evidence bar. The FDA has not yet accepted the filing, and the confirmatory study design, likely a concurrent standard-of-care control rather than sham surgery, is still being negotiated. Accelerated approval would require uniQure to confirm clinical benefit after launch, and a 12-patient efficacy dataset stacked against an external control remains the core regulatory risk.

Watch for three events: BLA acceptance within about 60 days, the priority review decision, and a four-year data readout promised before the end of the third quarter. If the agency accepts the external-control design, it validates a faster path other rare-disease gene-therapy programs are watching closely.

Source: uniQure AMT-130 BLA submission press release

What It Means for the Trade

The 4.7% drop to $46.23 on a filing announcement is the market pricing the review risk honestly. The BLA rests on a 12-patient efficacy dataset compared against a propensity-matched external control from Enroll-HD — not a randomized trial — and the FDA already pushed back once, in November 2025, before reversing course after a June 2026 Type B meeting. Filing is a procedural milestone, not a validation; the acceptance decision within about 60 days is the first real verdict, and the priority review request is the second. A $3.3 billion market cap on this structure means the stock is priced for a substantial probability of approval already, so any regulatory wobble gets amplified.

The asymmetry is the trade. If the FDA accepts the external-control design, it greenlights a pathway other gene-therapy programs in hard-to-trial diseases are watching closely — platform read-through beyond Huntington’s. If it balks again, QURE likely loses a third of its value overnight and the timeline stretches a year or more. That is a binary with a date, which means it is a position you size before the 60-day window, not after.

Mechanism and Market Context

The science is a clean one-gene story: Huntington’s comes from a toxic expanded huntingtin protein, and AMT-130 uses an AAV5-delivered microRNA to silence the gene at its source in the striatum — delivered by MRI-guided convection-enhanced neurosurgery. The three-year data showed a 75% slowing of cUHDRS progression in high-dose patients (p=0.003) against the matched external control. Note what that comparison is: propensity-score matching is sophisticated but not randomization — unmeasured differences between the treated cohort and the registry can masquerade as efficacy. That is precisely why the FDA’s comfort with this design is the whole ballgame.

The delivery complexity defines the launch economics even in a bull case: MRI-guided neurosurgical administration restricts the rollout to a limited number of specialized centers, meaning a Huntington’s launch is a multi-year capacity build, not a pharmacy event. With roughly 75,000 manifest patients in the US, EU, and UK and no disease-modifying alternative — Roche, PTC, and Alnylam all earlier — uniQure holds a multi-year lead worth protecting through review.

Risks and What Could Go Wrong

1. Filing rejection or acceptance-with-strings. The FDA can refuse to file, or accept with a confirmatory design that effectively re-opens the evidentiary question.
2. Small-n fragility. Twelve patients is a dataset where two or three atypical outcomes flip the story; the four-year readout promised before Q3’s end is the next datapoint.
3. Durability of effect. Silencing that fades after three years is a much smaller product than the current narrative assumes. Hold a sized position through the acceptance decision, and let the four-year data — not the press release — set the next level.